

## Summary Report of Financial Results for the 3<sup>rd</sup> Quarter of FY ended December 2014

November 7, 2014

Company Name: Carna Biosciences, Inc.  
 Stock exchange listing: Tokyo Stock Exchange (JASDAQ Growth)  
 Stock Code: 4572  
 URL: <http://www.carnabio.com/english/>  
 Representative: Kohichiro Yoshino, President  
 Contact: Norio Aikawa, Director  
 TEL +81-78-302-7039

(Rounding down to the nearest million yen)

### 1. Consolidated results for the 3<sup>rd</sup> quarter of FY2014 (January 1, 2014 - September 30, 2014)

(1) Business Results (Consolidated) (% indicates increases or decreases from the previous 3<sup>rd</sup> quarter)

	Total Revenue		Operating income		Ordinary income		Net income	
	million yen	%	million yen	%	million yen	%	million yen	%
3 <sup>rd</sup> quarter of FY2014	460	-17.9	-411	-	-388	-	-390	-
3 <sup>rd</sup> quarter of FY2013	560	51.3	-210	-	-191	-	-195	-

	Net income per share	Net income per share (diluted)
	yen	yen
3 <sup>rd</sup> quarter of FY2014	-47.15	-
3 <sup>rd</sup> quarter of FY2013	-25.97	-

Note: Net income per share of 3<sup>rd</sup> quarter of FY2013 and 2014(Diluted): No statement - We had net loss per share even though we had diluted shares.

### (2) Financial Condition (Consolidated)

	Total assets	Net assets	Equity ratio
	million yen	million yen	%
3 <sup>rd</sup> quarter of FY2014	1,647	1,304	78.6
FY2013	1,888	1,597	84.1

## 2. Cash Dividends

(criterion)	Dividends per share				
	End of 1 <sup>st</sup> quarter period	End of 2 <sup>nd</sup> quarter period	End of 3 <sup>rd</sup> quarter period	End of FY	FY
	yen	yen	yen	yen	yen
FY2013	-	0.00	-	0.00	0.00
FY2014	-	0.00	-		
FY2014 (forecast)				0.00	0.00

## 3. Forecast of Consolidated Drug Discovery Support segment for FY2014

(January 1, 2014 - December 31, 2014)

(% indicates increases or decreases from the previous year)

	Total revenue		Operating income		Ordinary income		Net income		Net income per share	
	million yen	%	million yen	%	million yen	%	million yen	%	yen	
FY2014	831	7.7	191	23.1	-	-	-	-	-	

Note: Omitted Forecast of Drug Discovery and Development segment

### \*Disclaimer regarding appropriate use of forecasts and related points of note

1. The above-mentioned forecasts are based on the information available on the date of release of these materials and on various assumptions made on the date of release of these material including uncertain factors and may affect future earnings. Actual operating results may differ significantly from those forecasts as a consequence of various factors.

2. Carna Biosciences split each share of common stock into 100 shares and changed the number of shares constituting one unit from 1 to 100 shares effective on 1st of Jan 2014, and this result per share is reflected this stock split.